Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production.

Gao Y, Zhang Y, Yao Y, Guan X, Liu Y, Qi X, Wang Y, Liu C, Zhang Y, Gao H, Nair V, Wang X, Gao Y.

Oncotarget. 2016 Dec 6;7(49):80275-80287. doi: 10.18632/oncotarget.13282.

2.

Soluble vascular endothelial growth factor receptors 2 (sVEGFR-2) and 3 (sVEGFR-3) and breast cancer risk in the Swedish Mammography Cohort.

Harris H, Wolk A, Larsson A, Vasson MP, Basu S.

Int J Mol Epidemiol Genet. 2016 Mar 23;7(1):81-6. eCollection 2016.

3.

The progress of angiogenic factors in the development of leukemias.

Han Y, Wang X, Wang B, Jiang G.

Intractable Rare Dis Res. 2016 Feb;5(1):6-16. doi: 10.5582/irdr.2015.01048. Review.

4.

Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.

Lai YD, Wu YY, Tsai YJ, Tsai YS, Lin YY, Lai SL, Huang CY, Lok YY, Hu CY, Lai JS.

Int J Mol Sci. 2016 Feb 5;17(2):214. doi: 10.3390/ijms17020214.

5.

Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.

Devery AM, Wadekar R, Bokobza SM, Weber AM, Jiang Y, Ryan AJ.

Int J Oncol. 2015 Sep;47(3):849-56. doi: 10.3892/ijo.2015.3082. Epub 2015 Jul 14.

6.

Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment.

Fujii H, Shin-Ya M, Takeda S, Hashimoto Y, Mukai SA, Sawada S, Adachi T, Akiyoshi K, Miki T, Mazda O.

Cancer Sci. 2014 Dec;105(12):1616-25. doi: 10.1111/cas.12547.

7.

EGF potentiation of VEGF production is cell density dependent in H292 EGFR wild type NSCLC cell line.

Ranayhossaini DJ, Lu J, Mabus J, Gervais A, Lingham RB, Fursov N.

Int J Mol Sci. 2014 Sep 30;15(10):17686-704. doi: 10.3390/ijms151017686.

8.

Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice.

Zeng Q, Wu Z, Duan H, Jiang X, Tu T, Lu D, Luo Y, Wang P, Song L, Feng J, Yang D, Yan X.

Protein Cell. 2014 Jun;5(6):445-56. doi: 10.1007/s13238-014-0047-y. Epub 2014 Apr 24.

9.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.

Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12.

10.

Decreased VEGF expression and microvascular density, but increased HIF-1 and 2α accumulation and EPO expression in chronic moderate hyperoxia in the mouse brain.

Benderro GF, Sun X, Kuang Y, Lamanna JC.

Brain Res. 2012 Aug 30;1471:46-55. doi: 10.1016/j.brainres.2012.06.055. Epub 2012 Jul 20.

11.

Challenges in design and characterization of ligand-targeted drug delivery systems.

Muro S.

J Control Release. 2012 Dec 10;164(2):125-37. doi: 10.1016/j.jconrel.2012.05.052. Epub 2012 Jun 15. Review.

12.

In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.

Yang L, You S, Kumar V, Zhang C, Cao Y.

J Exp Clin Cancer Res. 2012 May 1;31:40. doi: 10.1186/1756-9966-31-40.

13.

Changes in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factor.

Orgaz JL, Benguria A, Sanchez-Martinez C, Ladhani O, Volpert OV, Jimenez B.

Melanoma Res. 2011 Aug;21(4):285-97. doi: 10.1097/CMR.0b013e32834495c3.

14.

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.

You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM.

Cancer Res. 2011 Jul 15;71(14):4758-68. doi: 10.1158/0008-5472.CAN-10-2527. Epub 2011 May 25.

15.

Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Crose LE, Linardic CM.

Sarcoma. 2011;2011:756982. doi: 10.1155/2011/756982. Epub 2011 Jan 2.

17.

r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction.

Sullivan LA, Carbon JG, Roland CL, Toombs JE, Nyquist-Andersen M, Kavlie A, Schlunegger K, Richardson JA, Brekken RA.

PLoS One. 2010 Aug 6;5(8):e12031. doi: 10.1371/journal.pone.0012031.

18.

GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.

Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, Brekken RA.

BMC Cancer. 2010 Jul 30;10:397. doi: 10.1186/1471-2407-10-397.

19.

Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA.

J Oncol. 2010;2010:652320. doi: 10.1155/2010/652320. Epub 2010 Jun 10.

20.

Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Simpson-Haidaris PJ, Pollock SJ, Ramon S, Guo N, Woeller CF, Feldon SE, Phipps RP.

PPAR Res. 2010;2010:814609. doi: 10.1155/2010/814609. Epub 2010 Feb 28.

Supplemental Content

Support Center